a weak trendp = 0.095
There was also a weak trend towards abnormal LPS levels in non-obese RA patients ( p = 0.095), and abnormal fecal calprotectin levels in patients treated with TNF inhibitors ( p = 0.084) ( Table 3 ). 3.6.
There was also a weak trend towards abnormal LPS levels in non-obese RA patients ( p = 0.095), and abnormal fecal calprotectin levels in patients treated with TNF inhibitors ( p = 0.084) ( Table 3 ). 3.6.